Initial areas of focus for the collaboration will include improved delivery of injectable medicines with the goals of reducing pain, reducing the number of injections, and enabling better patient compliance and overall health; and the development of predictive clinical models that reduce the financial risks associated with drug development and that more effectively predict the outcome of new therapies in humans. Purdue researchers from the natural and physical sciences, engineering, and veterinary medicine will contribute to the largest strategic collaboration with a single company in the university's history, with the possibility of further collaboration in other areas in the future.
"Purdue has enjoyed a long history of engagement with Lilly. Now Lilly and Purdue University are entering into a new level of collaboration that will move us forward in areas core to both institutions," said the university's president, Mitch Daniels. "Our investment on campus in the life sciences announced in 2016 is leading to just the types of impact we hoped to effect."
"The biomedical revolution is upon us, but harnessing its full potential will require strong collaboration between academic research centers and industry partners," said David Ricks, chairman, president, and CEO of Eli Lilly. "We look forward to expanding our relationship with Purdue as we work together to discover breakthrough solutions for patients."